



**NLCRT**  
NATIONAL LUNG CANCER ROUNDTABLE

# 4<sup>TH</sup> ANNUAL MEETING

December 7-8, 2020

# Welcome from the NLCRT

Dear Conference Participants,

A warm welcome to the 4<sup>th</sup> Annual Meeting of the National Lung Cancer Roundtable (NLCRT)! The COVID-19 pandemic has turned 2020 into an unusual year for everyone. It has also provided us with unique opportunities, such as virtual platforms for meetings and conferences. NLCRT is leveraging its online presence this week to include the entire lung cancer community in this year's conference. We are proud of the NLCRT's work and look forward to a productive event.

The NLCRT, an American Cancer Society (ACS) initiative nationally sponsored by Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech, Lilly Oncology, Novartis, and Sanofi, is a national coalition of public, private, and voluntary organizations, and invited individuals, committed to fighting lung cancer through coordinated leadership, strategic planning, collaboration, advocacy and action. Currently, 147 of the key national organizations, including specialty medical organizations, federal and state health agencies, advocacy groups, health plans, cancer centers and academic institutions, and corporate affiliates are member organizations. Their representatives include nationally known experts, thought-leaders, and decision-makers in lung cancer. We welcome your participation in our shared work and encourage you to learn more about [NLCRT membership](#) on our website.

The NLCRT aims to stimulate multidisciplinary collaborations that drive actions to reduce lung cancer mortality through lung cancer awareness, risk reduction, early detection, and optimal diagnosis and therapy through public education, provider education, and health policy initiatives. The Roundtable has an ambitious goal of reducing the incidence and mortality from lung cancer in the United States.

In assembling the agenda for our 4<sup>th</sup> Annual Meeting, the theme **Forging the New Frontier of Lung Cancer** will feature Harry de Koning, MD, PhD, as the 2020 Keynote Speaker. Dr. de Koning, of the Erasmus Medical Center in Rotterdam, the Netherlands, is Principal Investigator of the Dutch-Belgian lung cancer screening trial (NELSON), which confirmed the findings of the National Lung Screening Trial of the mortality benefit of screening at-risk populations using low-dose CT screening, finding a 24% reduction in mortality after 10 years of screening.

The agenda will highlight the work of those who are shaping the future direction of lung cancer care and control over the past year through a series of presentations in areas such as screening, tobacco treatment, surgical, medical and radiation oncology, survivorship, disparities and policy. During the afternoon sessions each day, the NLCRT will showcase the work of its Task Groups along with their workplans for 2021. On Tuesday morning, NLCRT signature initiatives and projects will be described in detail along with ways in which these efforts will be propelled into action over the coming year. In addition, a brief poster session and a conversation with industry, payers and advocates focused on lung cancer biomarker testing will round out the content of the 2020 Annual Meeting.

Special thanks to the NLCRT Steering Committee, and our Task Group Co-Chairs, who have worked so hard to plan the Annual Meeting and create and advance our strategic objectives. If you have additional suggestions or feedback, please pass them along. Our goal is for you to emerge from the meeting feeling energized by our collective progress and empowered to work together to create more lung cancer survivors.

Again, welcome and thank you for joining us!

Sincerely yours,



*Ella A. Kazerooni, MD, MS  
NLCRT Chair  
University of Michigan*



*Douglas E. Wood, MD  
NLCRT Vice Chair  
University of Washington*



*Robert A. Smith, PhD  
NLCRT PI  
American Cancer Society*

# The National Lung Cancer Roundtable

The National Lung Cancer Roundtable (NLCRT) was created to stimulate multidisciplinary collaborations that drive actions to reduce lung cancer mortality. Since its formal launch in early-2017, the NLCRT has galvanized over 200 national and international subject matter experts (SMEs) and patient advocate representatives and 147 of the leading patient advocacy organizations, professional medical societies, state and national government agencies, cancer centers and academic institutions, health plans, and corporate associates to form the NLCRT. Our membership continues to grow.

Through coordinated leadership, strategic planning, advocacy, action and collaboration, the NLCRT's principal objective is to reduce the incidence and mortality from lung cancer and improve the quality of life of lung cancer survivors. To that end, the NLCRT:

- Creates a venue for lung cancer advocates, clinicians, researchers, and industry to coalesce and effect change
- Convenes task groups in key areas to improve lung cancer risk reduction, early detection, diagnosis, treatment and survivorship
- Disseminates actionable information to transform lung cancer screening, treatment, and survivorship.

The NLCRT employs a broad set of strategies to meet its objectives through the work of its task groups. The NLCRT is focused on: (1) influencing the uptake of lung cancer screening in a manner that is coordinated, and achieves high quality; (2) increasing tobacco treatment in the context of lung cancer screening; (3) supporting effective, efficient implementation of shared decision-making conversations in concert with primary care providers, focusing on diverse populations, and ongoing research and design related to improving that process; (4) promoting health care professional activation (increased awareness, action, coordination, and multi-disciplinary teams); (5) achieving guideline-adherent nodule management and biomarker testing for treatment planning, proper surgical staging, and triage for appropriate treatment; (6) identifying strategies to eliminate disparities in access to tobacco treatment, LDCT screening, and treatment; (7) overcoming the existence and influence of stigma, nihilism, and fatalism among the patient and provider communities, and the population as a whole; (8) addressing lung cancer in women; (9) supporting state-based initiatives that mirror the NLCRT initiatives at the national level; and (10) addressing key policy needs to support each of these objectives.

With collaboration and coordination, the NLCRT can further the mission of all member organizations. It can also identify and address issues and challenges that may be peripheral to an organization's mission, but are recognized as important and worthy of engagement as a collaborator. By accelerating the development of collaborative initiatives between organizations, the NLCRT has proved to be an effective and efficient platform that harnesses the collective power and expertise of the entire lung cancer community to address challenges.

Learn more at [nlcrt.org](http://nlcrt.org).

# Tips for Engagement

Here are some helpful tips to get the most out of the meeting.

## Engage on Social Media!

- Tweet using **#NLCRT2020**
- Tag **@NLCRTnews**



## Explore and Engage in the Event Virtual Space!

- Use the **Q&A feature** to ask questions.
- Use the **Chat feature** to comment and interact.
- **Learn about the speakers** from the biosketches in the program PDF.
- This event is being recorded and will be shared afterward.
- **Please stay for the entire program!**



## Interact on Slido!

- Open <https://www.sli.do/> and enter meeting code: **nlcrt2020**
- Ask Q&A questions.
- Participate in polls.
- Participate in quizzes.



# Tips for Maximizing Your Online Experience

## Use the Best Internet Connection You Can

- Using a wired internet connection is best because it is the most resistant to failure.
- Using a WiFi connection is more reliable than a cellular connection.

## Close Applications to Free Up Computing Power

- Virtual meetings can demand significant memory and processing power from your computer.
- Close unused applications during the session to free up your computing power. (e.g., Word, Excel, Outlook, VPN, and especially weather apps and other browser tabs).

## Access the Conference Site

- Click on the conference link in your conference email and enter your first and last names.
- Enter the email address that you used to register for the conference.
- Enter your verification code – you will receive a verification code via phone and email.
- Logging in will grant conference site access for 24 hours.
- When the time expires, simply repeat the steps above.

# Tips for Maximizing Your Online Experience, continued

## Prepare for Participating

- Block off your calendar to minimize distractions while you watch key sessions.
- Make the most of your time. Explore the online platform before the conference begins.
- Familiarize yourself with the layout of the conference apps.
- Have snacks close by so you won't miss anything while fetching food.

## During the Conference

- During the conference, take short physical breaks to stand and stretch. Take care of yourself!
- Organize a group chat with other attendees to highlight things to discuss together afterward. Plan to catch up and discuss key sessions or messages that interested you.
- Plan for replays by taking notes of sessions you want to watch again later.

# NLCRT Leadership



**Ella A. Kazerooni, MD, MS**  
Chair, NLCRT  
University of Michigan



**Douglas E. Wood, MD**  
Vice Chair, NLCRT  
University of Washington



**Robert A. Smith, PhD**  
Principal Investigator, NLCRT  
American Cancer Society

# NLCRT Staff



**Lauren S. Rosenthal, MPH**  
Director, NLCRT



**Kenly Burn**  
Project Specialist, NLCRT



**Dionne Christopher**  
Program Manager, Cancer  
Screening Center & NLCRT

# NLCRT Steering Committee



Joseph Chin, MD, MS



V. Paul Doria-Rose, DVM, PhD



Jill Feldman



Laurie Fenton Ambrose



Thomas Houston, MD



Bruce Johnson, MD



Jane Kim, MD, MPH



Bryan Loy, MD, MBA



Peter Mazzone, MD, MPH



Jamie Ostroff, PhD



Gerard Silvestri, MD, MS



Jamie Studts, PhD




Joelle Thirsk Fathi, DNP, ARNP



Richard Wender, MD



# Task Group Leadership



**Advanced Imaging**  
Daniel Sullivan, MD, Duke University  
Michael McNitt-Gray, PhD, UCLA



**Implementation Strategies**  
Charles White, MD, University of Maryland  
Carey Thomson, MD, MPH,  
Mt. Auburn Hospital/Beth Israel Lahey Health



**Lung Cancer in Women**  
Leah Backhus, MD, MPH, Stanford University  
M. Patricia Rivera, MD, UNC Chapel Hill



**Provider Engagement & Outreach**  
Thomas Houston, MD, AAFP  
Jan Eberth, PhD, University of South Carolina




**Policy Action**  
Ruth Carlos, MD, MS  
University of Michigan



**NLCRT**  
NATIONAL LUNG CANCER ROUNDTABLE

# Task Group Leadership



**Shared Decision-Making**  
Robert Volk, PhD, MD Anderson Cancer Center  
Peter Mazzone, MD, MPH, Cleveland Clinic



**State-Based Initiatives**  
Jessica Olson, PhD, MPH, Medical College  
of Wisconsin  
Timothy Mullett, MD, MBA, University of Kentucky



**Survivorship, Stigma & Nihilism**  
Jamie Studts, PhD, University of Colorado  
Lisa Carter-Harris, PhD, APRN, ANP-C,  
Memorial Sloan Kettering Cancer Center



**Tobacco Treatment**  
Jamie Ostroff, PhD, Memorial Sloan Kettering  
Cancer Center  
Joelle Thirsk Fathi, DNP, ARNP, CTTS, University of  
Washington



**Triage for Appropriate Treatment**  
Gerard Silvestri, MD, MS, MUSC  
Farhood Farjah, MD, MPH,  
University of Washington



**NLCRT**  
NATIONAL LUNG CANCER ROUNDTABLE



**2020 Keynote Speaker**  
**Harry de Koning, MD, PhD**  
Erasmus Medical Center  
Rotterdam, the Netherlands

Harry de Koning, MD, PhD, will be the 2020 Keynote Speaker. Dr. de Koning is a medically trained epidemiologist and Professor of Public Health & Screening Evaluation at Erasmus Medical Center, Rotterdam, the Netherlands. He is Principal Investigator of the NELSON Lung Screening Trial, which was the second randomized controlled trial to demonstrate the efficacy of LDCT lung cancer screening, and provided important new information on the effectiveness of lung cancer screening that influenced the USPSTF's 2020 draft update of the lung cancer screening recommendations, which lower both screening age and smoking history for eligibility.

Dr. de Koning's major scientific contributions are in the areas of (1) designing, running and evaluating (often large-scale) multidisciplinary, population-based, randomized controlled screening trials to establish the efficacy of screening, (2) evaluating active (inter-)national screening programs and clinical tests to establish effectiveness and (3) guiding public health policies on screening and primary prevention using predictions of favorable and unfavorable effects and the cost of interventions, based on micro-simulation modeling of the natural history of disease, risk-prediction modeling, and cost-effectiveness and cost-utility analyses. His team's multidisciplinary and international research results in recommendations on whether to introduce screening, surveillance or other preventive interventions for specific diseases and on policy decisions to introduce it in specific ways, either at the population level or in (high risk) patients.

Dr. de Koning designed the entire NELSON trial in all its facets (sole trial with different screening intervals). This trial was the first to show that lung nodules detected by low-dose CT scanning can be managed safely with conservative follow-up schedules when including volume-doubling times in the algorithm and is the largest trial without screening in the control arm.

# Agenda

Day #1: Monday, December 7, 2020

9:50 am ET

MEETING OPENS

10:00 am ET –  
10:45 am ET

WELCOME TO THE NLCRT 4<sup>th</sup> ANNUAL MEETING AND OPENING SESSION

**Welcome and Opening Remarks**

Ella Kazerooni, MD, MS, NLCRT Chair, *University of Michigan*

10:05 am ET

**Patient Story**

Millicent Wilson, *American Lung Association*

10:15 am ET

**Keynote Address**

Harry de Koning, MD, PhD, *Erasmus Medical Center, Rotterdam, the Netherlands*

10:50 am ET –  
1:00 pm ET

SESSION TWO: APPRAISING LUNG CANCER ACROSS THE CARE CONTINUUM

10:50 am ET –  
11:25 am ET

**Lung Cancer Screening**

**Moderator:** Peter Mazzone, MD, MPH, *Cleveland Clinic*

- **COVID-19 - Screening and Lung Nodule Management Guidelines:** Peter Mazzone, MD, MPH, *Cleveland Clinic*
- **Department of Veterans Affairs & GO<sub>2</sub> Foundation for Lung Cancer Collaboration:** Anita McGlothlin, *GO<sub>2</sub> Foundation for Lung Cancer*
- **First Million Screens in the American College of Radiology Lung Cancer Screening Registry:** Gerard Silvestri, MD, MS, *Medical University of South Carolina*
- **USPSTF Lung Cancer Screening Guidelines Update:** Ella Kazerooni, MD, MS, *University of Michigan*

11:30 am ET –  
12:00 pm ET

**Tobacco Treatment**

**Moderator:** Jamie Ostroff, PhD, *Memorial Sloan Kettering Cancer Center*

- **NCI Smoking Cessation at Lung Examination (SCALE) Collaboration:** Stephanie Land, PhD, *National Cancer Institute*
- **NCI Cancer Center Cessation Initiative (C3I):** Graham Warren, MD, PhD, *Medical University of South Carolina*
- **Surgeon General Report on Smoking Cessation:** Brenna VanFrank, MD, MSPH, *Centers for Disease Control and Prevention*

12:05 pm ET –  
12:40 pm ET

### Surgical, Radiation and Medical Oncology

**Moderator:** Bruce Johnson, MD, *Dana-Farber Cancer Institute*

- **Enforcing the Need for State-of-the-Art Surgical Interventions:** Brendon Stiles, MD, *Weill Cornell Medicine*
- **Stereotactic Radiotherapy Advancements:** Anurag Singh, MD, *Roswell Park Comprehensive Cancer Center*
- **Targeted Therapy Advancements:** Raymond Osarogiagbon, MBBS, *Baptist Cancer Center, Memphis*
- **COVID-19 in Patients with Lung Cancer:** Gregory Riely, MD, PhD, *Memorial Sloan Kettering Cancer Center*

12:45 pm ET –  
1:20 pm ET

### Disparities, Survivorship, Policy and Practice in Lung Cancer Care

**Moderator:** M. Patricia Rivera, MD, *University of North Carolina at Chapel Hill*

- **Addressing Disparities in Lung Cancer Screening and Access:** Louise Henderson, PhD, *University of North Carolina at Chapel Hill*
- **Fitness, Depression & Survivorship + COVID-19 in Lung Cancer Care** – Brett Bade, MD, *Yale University*
- **HEDIS Measure & Telehealth Related to Screening and Access** – Ruth Carlos, MD, MS, *University of Michigan*
- **Improving Access to Biomarker Testing** – Devon Adams, RN, MPH, ACS CAN

1:25 pm ET –  
2:15 pm ET

### SESSION THREE: NLCRT POSTER HIGHLIGHTS

*The poster session features 16 pre-recorded presentations that highlight lung cancer projects across the continuum of care. The moderated Question & Answer session will begin at 2:00pm ET.*

**Moderator:** Jill Feldman, *EGFR Resisters*

2:35 pm ET –  
4:40 pm ET

### SESSION FOUR: NLCRT TASK GROUP SHOWCASE

#### Co-Moderators:

Joelle Fathi, DNP, ARNP, *University of Washington*

Jamie Studts, PhD, *University of Colorado*

2:35 pm ET

### Provider Engagement and Outreach Task Group

**Chair:** Thomas Houston, MD, *American Academy of Family Physicians*

**Vice Chair:** Jan Eberth, PhD, *University of South Carolina*

#### Additional Presenters:

Jennifer Lewis, MD, MS, MPH, *Vanderbilt University*

Efren Flores, MD, *Massachusetts General Hospital*

Robert Smith, PhD, *American Cancer Society*

Celeste Worth, MCHES, *LuCa National Training Network*

3:05 pm ET

### Shared Decision-Making Task Group

**Chair:** Robert Volk, PhD, *MD Anderson Cancer Center*

**Vice Chair:** Peter Mazzone, MD, MPH, *Cleveland Clinic*

#### Additional Presenter:

Ronald Myers, DSW, PhD, *Thomas Jefferson University*

3:40 pm ET

### Lung Cancer Screening Implementation Strategies Task Group

**Chair:** Charles White, MD, *University of Maryland*

**Vice Chair:** Carey Thomson, MD, MPH, *Mt. Auburn/Beth Israel Lahey Health*

Additional Presenters:

Debra Dyer, MD, *National Jewish Hospital*

Joelle Fathi, DNP, ARNP, *University of Washington*

Peter Mazzone, MD, MPH, *Cleveland Clinic*

4:10 pm ET

### Tobacco Treatment in the Context of Lung Cancer Screening Task Group

**Chair:** Jamie Ostroff, PhD, *Memorial Sloan Kettering Cancer Center*

**Vice Chair:** Joelle Fathi, DNP, ARNP, *University of Washington*

4:40 pm ET –

### CLOSING REMARKS AND END OF DAY 1

4:45 pm ET

Ella Kazerooni, MD, MS, NLCRT Chair, *University of Michigan*

## Day #2: Tuesday, December 8, 2020

9:50 am ET

### MEETING OPENS

10:00 am ET –

### WELCOME TO DAY 2 OF THE NLCRT ANNUAL MEETING

10:40 am ET

#### Welcome and Opening Remarks

Douglas Wood, MD, NLCRT Vice Chair, *University of Washington*

10:05 am ET

#### Patient Story

Gina Kenney, *Patient Advocate*

10:15 am ET –

### National Estimates of Access to and Utilization of Lung Cancer Screening

10:40 am ET

- **State Variation in Low-Dose CT Scanning for Lung Cancer Screening in the United States:** Stacey Fedewa, PhD, MPH, *American Cancer Society*
- **Using Geospatial Analysis to Evaluate Access to Lung Cancer Screening in the United States:** Liora Sahar, PhD, GISP, *American Cancer Society*

10:45 am ET –

### SESSION SIX: NLCRT PRIORITY INITIATIVES AND SPECIAL PROJECTS

1:05 pm ET

10:45 am ET –

### NLCRT Highlights: Summits & Priority Initiatives

12:05 pm ET

**Moderator:** Gerard Silvestri, MD, MS, *Medical University of South Carolina*

- **NLCRT Strategic Plan:** Robert Smith, PhD, NLCRT PI, *American Cancer Society*
- **Eliminating Lung Cancer Stigma – A National Initiative**
  - **Advocate Perspective:** Dusty Donaldson, *Dusty Joy Foundation, LungCAN*
  - **Summit and Initiative Overview:** Lisa Carter-Harris, PhD, APRN, ANP-C, *Memorial Sloan Kettering Cancer Center*
  - **Stigma Initiative Strategic Plan:** Jamie Studts, PhD, *University of Colorado*

- **Optimizing Lung Cancer Biomarkers in Practice – A National Initiative**
  - **Advocate Perspective:** Gina Hollenbeck, RN, BSN, *ALK Positive*
  - **Summit and Initiative Overview:** M. Patricia Rivera, MD, *University of North Carolina at Chapel Hill*
  - **Stakeholder Confessions on Barriers to Comprehensive Biomarker Testing:** Farhood Farjah, MD, MPH, *University of Washington*
  - **Biomarker Initiative Strategic Plan:** Bruce E. Johnson, MD, *Dana-Farber Cancer Institute*

12:10 pm ET –  
1:05 pm ET

#### NLCRT Highlights: Priority Projects

**Moderator:** Richard Wender, MD, Penn Medicine

- **State Lung Cancer Coalition-Building Guide:** Jessica Olson, PhD, *Medical College of Wisconsin*
- **High Quality Lung Cancer Screening and Nodule Surveillance Programs – Modeling for Implementation and Programmatic Expansion:** Carey Thomson, MD, MPH, *Mt. Auburn Hospital/Beth Israel Lahey Health*
- **Partnership with American Academy of Family Physicians – Shared Decision-Making Tools:** Robert Volk, PhD, *MD Anderson Cancer Center*
- **American Cancer Society Regional Cancer Control Update:** Letitia Thompson, MPA, *American Cancer Society*

1:10 pm ET –  
2:25 pm ET

#### SESSION SEVEN: ADVOCACY/HEALTH PLAN/INDUSTRY PANEL

*Representatives from Industry, Payer, and Advocacy organizations will discuss the challenges they regard as most important to ensure that biomarker testing for patients with advanced NSCLC becomes routine, efficient, and high quality, and ways in which their organizations can contribute to a national collective initiative to advance biomarker testing and ensure patients receive state of the art care.*

**Moderator:** Robert Smith, PhD, NLCRT PI, *American Cancer Society*

#### Panelists:

Jennifer Norton, *Amgen*

Katy Miller, *AstraZeneca*

Emily Leong, *Genentech*

Bryan Loy, MD, MBA, *Humana*

Jill Feldman, *EGFR Resisters*

Upal Basu Roy, PhD, MPH, *LUNGeVity Foundation*

2:30 pm ET –  
4:35 pm ET

## SESSION EIGHT: TASK GROUP SHOWCASE

### Co-Moderators:

Jane Kim, MD, MPH, *Department of Veterans Affairs*  
Douglas Wood, MD, *University of Washington*

2:30 pm ET

### Lung Cancer in Women Task Group

**Chair:** Leah Backhus, MD, MPH, *Stanford University*  
**Vice Chair:** M. Patricia Rivera, MD, *University of North Carolina at Chapel Hill*  
**Additional Presenter:**  
Kim Sandler, MD, *Vanderbilt University*

3:00 pm ET

### State-Based Initiatives

**Chair:** Jessica Olson, PhD, *Medical College of Wisconsin*  
**Vice Chair:** Timothy Mullett, MD, MBA, *University of Kentucky*  
**Additional Presenters:**  
Katie Bathje, *American Cancer Society*  
Amy Copeland, MPH, Consultant, *State-Based Initiatives Task Group*

3:35 pm ET

### Advanced Imaging Task Group

**Chair:** Daniel Sullivan, MD, *Duke University*  
**Vice Chair:** Michael McNitt-Gray, PhD, *University of California, Los Angeles*

4:05 pm ET

### Policy Action Task Group

**Chair:** Ruth Carlos, MD, MS, *University of Michigan*  
**Additional Presenters:**  
Andrea Borondy Kitts, MS, MPH, *Rescue Lung Rescue Life*  
Sarah Downer, JD, *Center for Health Law and Policy Innovation, Harvard*

4:35 pm ET –  
4:45 pm ET

## CLOSING REMARKS AND END OF ANNUAL MEETING

Ella Kazerooni, MD, MS, NLCRT Chair, *University of Michigan*  
Douglas Wood, MD, NLCRT Vice Chair, *University of Washington*



# Speaker Biosketches

## Devon Adams, RN, MPH

Devon Adams is a Senior Analyst, Policy and Legislative Support at the American Cancer Society Cancer Action Network. He works on issues in the Emerging Science portfolio which includes clinical trials, research and development of cancer drugs, and cancer biomarker testing. He has experience in health policy, government relations, and clinical care having practiced as a registered nurse.

## Leah Backhus, MD, MPH, FACS

Leah Backhus MD MPH FACS trained in general surgery at the University of Southern California and cardiothoracic surgery at the University of California Los Angeles. She practices at Stanford Hospital and is Chief of Thoracic Surgery at the VA Palo Alto. Her surgical practice consists of general thoracic surgery with special emphasis on thoracic oncology and minimally invasive surgical techniques. She heads up the Thoracic Surgical Health Services Research group in the Division of Thoracic Surgery, and has grant funding through the Veterans Affairs Administration with a VA Merit Award and is Co-PI on an RO1 translational study examining diaphragm dysfunction among esophagectomy patients. She serves as an ad hoc reviewer for NIH Study Section on Image Guided Interventions and Surgery (IGIS). Her current research interests are in cancer surveillance and survivorship care in evaluating needs, quality of life, adherence to national standards of care. She is a member of the National Lung Cancer Roundtable of the American Cancer Society serving as Chair of the Task Group on Lung Cancer in Women. She also has served as a professional member of the Patient Centered Outcomes Research Institute (PCORI) Advisory Panel on Improving Healthcare Systems. She is a member of the American Association for Thoracic Surgery and is a member of the Board of Directors of the Society of Thoracic Surgeons. As an educator, Dr. Backhus is the Associate Program Director for the Stanford Thoracic Track Residency and serves as the Chair of the ACGME Review Committee for Thoracic Surgery which is the accrediting body for all cardiothoracic surgery training programs in the US.

## Brett Bade, MD

Brett Bade, MD, is a pulmonary and critical care physician at Yale University School of Medicine and the West Haven Veterans Affairs Hospital. His career focus is to advance lung cancer survivorship care via optimizing quality of life and functional independence. As a clinician caring for patients with lung cancer and chronic lung disease, it is clear to him that quality of life, symptom burden, and overall outcome are related to physical activity level. Further, implementation of treatments to address physical inactivity in lung cancer are poorly-understood and under-utilized. It is his belief that lung cancer survivorship should assess a patient's symptoms, quality of life, physical function, and baseline activity level at the time of diagnosis and manage these issues concurrently with cancer-directed therapy. He has additional interests in lung cancer outcomes research, lung cancer screening implementation, and use of lung cancer biomarkers to predict treatment and outcomes. His research projects include physical activity implementation utilizing mobile health (mHealth) techniques, pulmonary rehabilitation in lung cancer, and the impact of medical and psychiatric comorbidities on lung cancer outcomes.

# Speaker Biosketches

## Upal Basu Roy, PhD, MPH

Upal Basu Roy is Vice President of Research at LUNGeivity Foundation, the pre-eminent lung cancer patient advocacy group in the United States. In this capacity, he directs both the Translational Science Research Program and the Patient-Focused Research Center (Patient FoRCe). Within the Translational Science Research Program, Upal guides the award administration and peer review of lung cancer translational research grants, as well as the monitoring and evaluation of research projects that focus on improving outcomes via early detection and improved treatment options. Within Patient FoRCe, he designs, implements, and manages all phases of research studies that seek to understand the lung cancer patient experience and identify unmet needs in education and access to care. Specifically, he manages protocol development to project execution to recommendations on how to incorporate Patient FoRCe research study findings into clinical practice. Upal has spearheaded several multi-stakeholder research projects that aim to increase access to lung cancer screening, biomarker testing, and clinical trials for lung cancer patients.

Upal firmly believes that lung cancer advocacy is a continuum that ranges from activities focused on individual patients to those spanning communities, organizations, and policy makers. As a patient research advocate, he works with national organizations such as the United States Food and Drug Administration, the National Cancer Institute, other patient advocacy groups, and pharma partners on policy initiatives to make clinical trials more streamlined and patient-centric.

Upal has over 10 years of translational cancer research experience in the laboratory. He has a PhD in Cancer Biology and an MPH in Global Health Policy and Management. Upal is a published author and serves as peer reviewer for translational science and public health journals.

## Andrea Borondy Kitts, MS, MPH

Andrea Borondy Kitts is a retired engineering executive with 32 years of experience in Aerospace. She lost her husband to lung cancer in April 2013 and is now a lung cancer and patient advocate and consultant. She is the patient representative for the Lahey Hospital & Medical Center CT lung screening program where she assists with research and helps provide a patient perspective to the program. She is a recognized international speaker on lung cancer screening and on patient and family centered care. Andrea is also an Associate Editor for the Journal of the American College of Radiology (JACR), a member of the Massachusetts Comprehensive Cancer Prevention & Control Network's secondary prevention subcommittee focused on lung screening, the National Lung Cancer Round Table, the American Association of Medical Colleges Telehealth Advisory Committee, and the NAM Action Collaborative on Clinician Well Being and Resilience. She is the COO of Prosumer Health, a start-up company that is developing a smartphone accessible, AI-driven, evidenced-based health maintenance and improvement platform for consumers. She volunteers for the American Lung Association. Andrea has a BS in Mechanical Engineering from UVM, a MS in Management from MIT and a Master's in Public Health degree from the University of Connecticut. Andrea tweets as @findlungcancer and can be reached at [borondy@msn.com](mailto:borondy@msn.com).

# Speaker Biosketches

## Ruth Carlos, MD, MS, FACR

Ruth C. Carlos, MD, MS, FACR is Professor of Radiology and Assistant Chair for Clinical Research at the University of Michigan. She has been named the first woman editor-in-chief of a major radiology journal, the Journal of the American College of Radiology (JACR) that informs the management and practice of radiology.

Dr. Carlos has received numerous awards and honors. She is an elected fellow of the American College of Radiology, and the Society of Computed Tomography and Magnetic Resonance. She received the Gold Medal from the Association of University Radiologists, Distinguished Educator Award from the Radiological Society of North America, the Stanford Medicine X Research Challenge Grand Prize. A funded investigator of the National Institutes of Health, she has been inducted into the Academy of Radiology Research Council of Distinguished Investigators.

She served as President of the American Roentgen Ray Society, the Association of University Radiologist and the Radiology Alliance for Health Services Research in Radiology. She served as Vice-Chair of the University of Michigan Senate Advisory Committee on University Affairs, advising the President and Provost on faculty issues.

She lends her expertise in multispecialty guideline development to the National Quality Forum and the Joint Commission. She holds leadership positions in the ECOG-ACRIN, the largest NIH funded multidisciplinary multicenter clinical trials group focusing on imaging trials. She is co-PI and co-I on numerous clinical trials on prevention, surveillance and cancer care delivery. She co-chaired the National Cancer Institute (NCI) Cancer Care Delivery Research (CCDR) Development Committee and is a member of the NCI CCDR Steering Committee.

Dr. Carlos chairs the GE AUR Research Radiology Academic Fellowship (GERRAF), the oldest national program supporting early stage radiologists in health services research and care delivery. She is a frequent guest speaker nationally and internationally.

## Lisa Carter-Harris, PhD, APRN, ANP-C, FAAN

Dr. Lisa Carter-Harris is a behavioral scientist with over 15 years of clinical experience as an adult nurse practitioner. She completed her PhD at the University of Louisville in 2013 and a 2-year postdoctoral fellowship at Indiana University in Behavioral Oncology in 2015. She was inducted as a Fellow in the American Academy of Nursing for her work in patient-clinician communication in complex cancer screening decisions in 2018. She is currently an Associate Attending Behavioral Scientist and the Associate Research Director of the Tobacco Research, Training & Treatment Lab in the Department of Psychiatry & Behavioral Sciences at Memorial Sloan Kettering Cancer Center in New York City. Prior to joining Memorial Sloan Kettering, Dr. Carter-Harris was an Assistant Professor at Indiana University School of Nursing and Full Member of the Cancer Prevention & Control Program of Indiana University Simon Cancer Center. Dr. Carter-Harris has also been an Affiliate Investigator at Kaiser Permanente Washington Health Research Institute in Seattle since 2016.

# Speaker Biosketches

Dr. Carter-Harris' research focuses on understanding the many factors that influence the decision-making process in lung cancer screening decisions as well as actual screening behavior. She has a particular passion for understanding how stigma influences the decision to screen, or not, for lung cancer, and has been funded by the National Cancer Institute, American Lung Association, American Cancer Society, Cancer Research Network, Indiana University Simon Cancer Center, and Memorial Sloan Kettering Cancer Center's Population Science Research Program. She has been a strong advocate of understanding the patient perspective in lung cancer screening and credits the many wonderful individuals who have been involved in her studies for shaping her perspective on research and care in lung cancer. Dr. Carter-Harris was recently appointed to the Editorial Board of *Nursing Research*, the scientific journal of the American Academy of Nursing. She also serves as an executive board member of the Cancer Prevention and Control Board of the Centralized Institutional Review Board of the National Cancer Institute as well as many academic and national committees aimed at improving cancer prevention, early detection and decreasing inequities in care.

## Dusty Donaldson, MA

Dusty Donaldson is executive director of the Dusty Joy Foundation (LiveLung), a 501(c)(3) nonprofit with a focus of advancing lung cancer awareness, early detection and compassion for people impacted by lung cancer. Dusty coauthored the book "The ABCs of Lung Cancer for Patients and Advocates." She is co-chair of the Lung Cancer Action Network (LungCAN) and serves as a reviewer for lung cancer research proposals. She is a contributing writer for [www.lungcancer.net](http://www.lungcancer.net) and serves on the National Lung Cancer Roundtable's Survivorship, Stigma & Nihilism Task Group. Prior to being diagnosed with early-stage lung cancer in 2005, Dusty was a journalist and public relations professional with undergraduate and graduate degrees in journalism.

## Sarah Downer, JD

Sarah Downer is the Associate Director of Whole Person Care at the Center for Health Law and Policy Innovation of Harvard Law School, where she uses law and policy as tools to encourage person-centered care at every point of interaction with the healthcare system. Ms. Downer created the Center's Social Determinants of Health Law Lab, a project dedicated to analyzing novel legal issues that arise when the healthcare system interacts with individuals and communities in new ways. She has conducted policy analysis that identifies pathways to sustainable funding for oncology navigation, Community Health Workers, and nutrition interventions for cancer patients. She is a co-author of the forthcoming issue brief: Radon Risk Reduction: A Fractured Policy Landscape.

## Debra S. Dyer, MD, FACR

Dr. Debra Dyer is Professor and Chair of Radiology at National Jewish Health. received her bachelor of science degree from Ohio State University and a master of science in public health degree from Case Western Reserve University. She earned her medical degree from George Washington University, where she also did an internship in Internal Medicine. Dr. Dyer completed her residency in diagnostic radiology and a fellowship in chest radiology and mammography at the University of Colorado.

# Speaker Biosketches

Dr. Dyer joined National Jewish Health in 1993 and became Chair of the Department of Radiology in 2013. She is a diplomat of the American Board of Radiology. She serves as Chair of the American College of Radiology Lung Cancer Screening 2.0 Committee. Dr. Dyer is on the Scientific Advisory Board of the GO2 Foundation for Lung Cancer. She is Immediate Past-Chair of the Colorado Cancer Coalition.

Her research interests include lung cancer screening CT and lung nodule management. She has presented nationally at numerous professional meetings and her research has been published in several peer-reviewed journals.

## Jan Eberth, PhD, MPH

**Jan Eberth** is an Associate Professor in the Department of Epidemiology and Biostatistics at the University of South Carolina and the Director of the Rural and Minority Health Research Center. Dr. Eberth received her PhD from the University of Texas School Of Public Health and a postdoctoral fellowship from MD Anderson Cancer Center. The focus of her research is cancer health disparities, particularly socioeconomic and structural barriers that impede access and utilization of cancer screening and timely treatment. She has published >100 articles in this area of research, with unique expertise in identifying barriers and facilitators to implementation of evidence-based policies/practices including low-dose CT screening for lung cancer. She is the co-chair of the Cancer Prevention and Control Research Network's Rural Cancer Workgroup, Vice-Chair of the National Lung Cancer Roundtable Provider Engagement and Outreach Task Group, and Fellow and President-Elect of the American College of Epidemiology.

## Farhood Farjah, MD, MPH, FACS

Dr. Farhood Farjah is an Associate Professor of Surgery and Endowed Chair in Lung Cancer Research at the University of Washington. He is a member of the Multidisciplinary Thoracic Oncology Team at the Seattle Cancer Care Alliance. In his role as Associate Medical Director for the University of Washington Surgical Outcomes Research Center, Farhood helps train the next generation of surgeon scientists. He is currently the Principal Investigator of a National Cancer Institute funded study of individuals with incidentally detected lung nodules that seeks to understand the relationship between the intensity of diagnostic evaluation and patient outcomes and healthcare costs. In addition to his work with the National Lung Cancer Roundtable, he serves on several committees for the Society of Thoracic Surgeons, American College of Chest Physicians, and the National Comprehensive Cancer Network. Farhood also serves on the Editorial Board for CHEST, Annals of Thoracic Surgery, and the Journal of Thoracic and Cardiovascular Surgery.

# Speaker Biosketches

## Joelle Fathi, DNP, RN, ARNP, CTTS

Joelle Fathi is an Adult Acute Care Nurse Practitioner and Certified Tobacco Treatment Specialist who has dedicated the majority of her clinical career to oncology, including integral roles in thoracic surgery, pulmonary medicine, and lung cancer screening. She is a Clinical Associate Professor in the Department of Biobehavioral Nursing and Health Informatics at the University of Washington School of Nursing, has spent over 20 years providing direct patient care, and serves at local, national, and global levels as an expert and advocate in tobacco control.

Dr. Fathi is committed to preventing cancer and chronic disease while optimizing health outcomes through comprehensive patient education and innovation through technology. She has served as the Director of Nursing Practice and Health Policy for the Washington State Nurses Association and is a member of the Washington State Telehealth Collaborative. Dr. Fathi is the lead or co-author of numerous publications.

## Stacey Fedewa, PhD, MPH

Stacey Fedewa is an epidemiologist and senior principal scientist in the Screening and Risk Factors Surveillance Team within the Data Sciences Department at the American Cancer Society (ACS). She is responsible for cancer screening and early detection research and examines disparities and access to cancer screening and the quality of it. She also examines how health policies and public health recommendations influence screening utilization and early detection. Fedewa's work has been used to inform national roundtables on colorectal cancer screening, HPV vaccination, and lung cancer.

## Jill Feldman

Jill Feldman is a lung cancer patient and advocate. When Jill was 13 years old, she lost her dad and two grandparents to lung cancer and then her mom and close aunt died of lung cancer when she was in her 20's. She became a volunteer, an advocate and past president of LUNGevity Foundation before the unthinkable happened. In 2009, at 39 years old with four small children, Jill herself was diagnosed with EGFR positive lung cancer.

Jill continues to be involved with LUNGevity. She is also Deputy Chair of IASLC's patient advisory board and a member of The Chicago Institute of Translational Medicine's patient advisory board. Jill is committed to understanding and promoting patient-centered research as a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, as a planning committee member on IASLC's North America Conference on Lung cancer and as a member of the ECOG-ACRIN Research Group's patient advocate committee and thoracic committee. Jill has presented patient perspectives at conferences, including the World Conference on Lung Cancer hosted by IASLC and the virtual ASCO Education Program. She is a co-author of the ASTRO Guidelines for SBRT in early stage lung cancer that was published in an ASCO special article in the Journal of Clinical Oncology.

In 2017, Jill co-founded the EGFR Resisters, a grassroots, patient-driven community committed to accelerating research that will prolong and better the lives of people diagnosed with EGFRm lung cancer. Jill also continues to share her story in the media and at various events and participates in countless advocacy opportunities to shine a light on lung cancer and end the stigma associated with it.

# Speaker Biosketches

## Efrén J. Flores, MD

Efrén J. Flores, MD, currently serves as a board-certified staff radiologist in Thoracic and Emergency Radiology at Massachusetts General Hospital (MGH) and is an Assistant Professor in Radiology at Harvard Medical School. Before this position, Dr. Flores graduated from the University of Puerto Rico Medical School and trained in radiology at MGH, a Harvard Medical School affiliate. Dr. Flores' research focuses on identifying social determinants of health impacting access to radiology among vulnerable patient populations and use this to inform the development and implementation of novel outreach programs to enhance health equity. His current and past funded research projects include improving access to lung cancer screening among individuals from low socioeconomic backgrounds, Latino communities, and individuals with serious mental illness. Dr. Flores' research has led him to scientific presentations at national meetings and has also published his work in multiple peer-reviewed scientific journals. In recognition of Dr. Flores work in this area, he was appointed Officer for Radiology Community Health & Equity in the Massachusetts General Hospital Department of Radiology in 2018. Dr. Flores also serves on local and national committees, including the MGH Executive Committee on Community Health, the American Cancer Association National Lung Cancer Roundtable Provider Outreach Committee, and the American College of Radiology Lung Cancer Screening 2.0 and Patient and Family-Centered Care committees, among others.

## Louise M. Henderson, PhD

Louise M. Henderson, PhD, is a Professor of Radiology and Epidemiology at the University of North Carolina at Chapel Hill, NC. She is a cancer epidemiologist and health services researcher whose work focuses on evaluating the benefits and harms of cancer screening and outcomes in diverse settings. Her research portfolio includes examining access to and disparities in lung cancer screening, assessing the comparative effectiveness of emerging imaging technologies, and evaluating the impact of comorbidities and functional limitations on lung cancer screening. Dr. Henderson leads the North Carolina Lung Screening Registry, an NIH/NCI funded initiative to provide evidence on lung cancer screening with low dose computed tomography in a general population to inform the delivery, quality, and outcomes of lung cancer screening as it diffuses into clinical practice. Dr. Henderson is a contributing member to the NLCRT Lung Cancer in Women Task Group and the Triage for Appropriate Treatment Task Group.

## Gina Hollenbeck, RN, BSN

Gina Hollenbeck is a Stage IV Lung Cancer survivor. She is a wife and mother of two boys. Gina is the President of ALK Positive, a patient-driven group dedicated to advancing research and awareness for ALK positive lung cancer. They have funded over \$1M in research grants for ALK Positive lung cancer. She is a driven advocate for lung cancer research, early detection, and biomarker testing.

## Thomas P. Houston, MD

Dr. Houston is a graduate of the University of Mississippi School of Medicine. After a 10-year career in academic family medicine, he directed the American Medical Association's tobacco control and public health advocacy programs. From 2003 to 2005, he held the Jim Finks Chair in Health Promotion at LSU Health Sciences Center in New Orleans and was Professor of Public Health and Family Medicine. From 2005-2016, he worked at the McConnell Heart Health Center in Columbus and directed tobacco cessation and policy initiatives for OhioHealth. He is currently Adjunct Professor in the Department of Family Medicine at The Ohio State University. He is past-president of the Ohio Academy of Family Physicians.



# Speaker Biosketches

## Bruce E. Johnson, MD, FASCO

Bruce E. Johnson, MD is the Chief Clinical Research Officer at Dana-Farber Cancer Institute, Institute Physician at Dana-Farber Cancer Institute and Brigham and Women's Hospital, and Professor of Medicine at Harvard Medical School. His laboratory-based research is devoted to testing novel therapeutic agents for their efficacy against lung cancer and other thoracic malignancies.

Dr. Johnson is a member of the American Association of Physicians. He served on the American Society of Clinical Oncology (ASCO) Board of Directors from 2008-2011, received the ASCO Cancer Foundation's Translational Research Professorship in 2008, and was selected as a Fellow of the American Society of Clinical Oncology in 2012. Dr. Johnson will begin serving as ASCO President-Elect in June of 2016. He also was awarded the International Association for the Study of Lung Cancer (IASLC) 2010 Scientific Award, given to an IASLC scientist for "life-time scientific contribution in thoracic malignancy research and who has also contributed to the organization's development." He was one of the leaders of the team awarded the American Association for Cancer Research (AACR) 2010 Team Science Award that "recognizes an outstanding interdisciplinary research team for its innovative and meritorious science that has advanced or likely will advance our fundamental knowledge of cancer or a team that has applied existing knowledge to advance the detection, diagnosis, prevention, or treatment of cancer."

## Ella A. Kazerooni, MD, MS, FACR, FSABI, FCCP

Ella A. Kazerooni, MD is a Professor of Radiology & Internal Medicine, and serves as the Associate Chief Clinical Officer for the Diagnostic and Clinical Information Oversight Team within the University of Michigan Medical Group (UMMG). She received her medical degree and completed her diagnostic radiology residency at University of Michigan in Ann Arbor, and fellowship at Massachusetts General Hospital/Harvard Medical School, joining the faculty at the University of Michigan in 1992.

She has served many roles in organized radiology, including president of the American Roentgen Ray Society, the Society of Thoracic Radiology, the Association of University Radiologist and the Radiology Alliance for Health Services Research in Radiology, a member of the American College of Radiology's Board of Chancellors and Executive Committee and Trustee of the American Board of Radiology. She is the inaugural chair of the American Cancer Society's Lung Cancer Roundtable, dedicated to creating lung cancer survivors through early detection and screening, improvements and access to modern diagnostics and treatments.

She is a frequently invited guest speaker at academic institutions and national/international meetings with expertise in lung cancer screening, and both interstitial and obstructive lung diseases is sought after by professional organizations developing multispecialty guidelines in radiology, pulmonary medicine and cardiovascular diseases with organizations such as the American College of Radiology (ACR), the American College of Cardiology Foundation and the National Quality Foundation. She currently is the Executive Sponsor of lung cancer screening activities of the ACR, where she also chairs the lung cancer screening registry and the LungRADS committee, and serves as the vice-chair of the National Comprehensive Cancer Network Guideline on Lung Cancer Screening.



# Speaker Biosketches

## Jane Kim, MD, MPH

As Chief Consultant, Dr. Jane Kim serves as the principal adviser to VHA on all issues related to preventive medicine and is responsible for promoting the expansion and improvement of clinical, research, training, and educational activities associated with the VHA preventive services through the design, development, and implementation of related policies and programs. Board-certified in preventive medicine and internal medicine, she also currently serves as an Associate Professor in Duke University's Department of Medicine.

## Jennifer Lewis, MD, MS, MPH

Dr. Jennifer Lewis is an Assistant Professor in the Division of Hematology and Oncology at Vanderbilt University Medical Center and staff physician at VA Tennessee Valley Healthcare System. Her research is focused in implementation science and translating lung cancer early detection and prevention into clinical practice. She is leading an evaluation of lung cancer screening programs participating in the VA-Partnership to increase Access to Lung Screening (VA-PALS) and is an awardee of Vanderbilt's V-STTaR K-12 program. During her time in this program, she will be conducting an in-depth exploration of healthcare provider engagement in lung cancer screening as well as developing strategies to support providers in performing evidence-based lung cancer screening.

## Stephanie Land, PhD

Stephanie Land, Ph.D., is a Program Director and Statistician in the Behavioral Research Program Tobacco Control Research Branch (TCRB) at the National Cancer Institute (NCI). Her areas of focus are tobacco use among patients in the settings of cancer prevention, screening, treatment, and survivorship. She is a member and past chair of the Division of Cancer Control and Population Science Clinical Trials Coordination Group. Formerly, she was a member of the NCI Special Studies Institutional Review Board and Associate Editor for the Journal of Clinical Oncology and a member of the CPCR Tobacco/Lung Cancer Working Group. She serves on the American Association for Cancer Research (AACR) Tobacco and Cancer Subcommittee and is chair of the NCI-AACR Cancer Patient Tobacco Use Assessment Task Force. She is the NCI lead for the Smoking Cessation At Lung Examination (SCALE) Collaboration, a collaboration that will share data and methods across 8 funded projects to pursue research on cessation interventions that are efficacious and feasible in lung cancer screening clinics.

Dr. Land has more than 90 research publications in print. From 1999-2011, she was a statistician in the National Surgical Adjuvant Breast and Bowel Project (NSABP), an NCI-funded clinical trials cooperative group that conducted multi-center phase III trials for breast and colorectal cancer. Her primary role in the NSABP was as the lead statistician for the Behavioral and Health Outcomes Program. She also collaborated with members of the University of Pittsburgh Cancer Institute Lung and Thoracic Malignancies Program from 1999-2011 and served as the lead statistician for the Lung Cancer Specialized Program of Research Excellence (SPORE) from 2002-11, directing the Core through two competing renewals. Before coming to NCI, Dr. Land participated in the Community Clinical Oncology Program (CCOP) Research Priorities Strategic Planning Committee (NCI), Subcommittee H (reviewing cooperative groups), the NCI Symptom Management and Quality of Life Scientific Steering Committee, and numerous NCI grant review panels. Dr. Land earned a doctorate in statistics from Stanford University.

# Speaker Biosketches

## Emily Leong

Emily Leong is a Marketing Team Director for Oncology Targeted Therapies at Genentech and leads the Rozlytrek (entrectinib) marketing team. Prior to this role, Emily has held several roles in different leadership capacities across the Genentech organization in product development, portfolio management, global product strategy, and US commercial. Emily earned a masters in the Business of Bioscience from the Keck Graduate Institute at the Claremont Colleges and a BS in Biological Sciences and Computer Science & Engineering from University of California, San Diego.

## Bryan Loy, MD, MBA

Bryan Loy MD, MBA is an industry recognized physician executive. He is a corporate medical director for Humana, a Fortune 100 health insurance company. Board certified in anatomic and clinical pathology and hematology,

Dr. Loy currently leads Humana's cancer care strategy, including quality and value initiatives for laboratory, medical oncology and radiation oncology.

He has 19+ years of experience in evaluating drugs and biologics, medical devices, laboratory tests and innovations including both effectiveness and payment. He is well experienced in accelerating the appropriate adoption of new technology. He is an oncology and laboratory subject matter expert for pharmacy and therapeutics committees, policy development committees and completed his 3rd year as an advisor and co-chair for the Center for Medicare and Medicaid Services (CMS) advisory panel designed to evaluate appropriate payment for new complex lab tests. He works with the nation's most prominent commercial labs and oncology groups to implement cancer quality initiatives in all 50 states. He collaborates directly with industry leading medical oncologists and practices committed to improving the patient experience.

A nationally recognized speaker, panelist, and author, Dr. Loy routinely presents on innovative cancer initiatives, the evolving landscape of health care delivery and population health initiatives. He's helped 100000+ member employer groups understand medical cost and utilization and created strategies improving quality of care and value while improving the employee experience. He is co-chair for a large public-private partnership employing new population health technology combined with community collective impact initiatives to improve referral processes to agencies and resources that address social determinants of health.

In previous roles, he has served as a medical director for a multi-state Medicare contractor and as Chief Medical Officer for an innovative lab focused on tailoring treatment for breast and ovarian cancer patients. Dr. Loy received his MBA (with distinction) from the University of Louisville and his MD from the University of Louisville. Dr. Loy continues to research and publish in population health, oncology, and molecular medicine.

## Peter J. Mazzone, MD, MPH, FCCP

Peter Mazzone is the Director of the Lung Cancer Program and Lung Cancer Screening Program for the Respiratory Institute of the Cleveland Clinic. Dr. Mazzone received his medical degree from the University of Western Ontario and his Masters in Public Health from Cleveland State.



**NLCRT**  
NATIONAL LUNG CANCER ROUNDTABLE

# Speaker Biosketches

Dr. Mazzone's research has focused on many aspects of the Pulmonologists' role in the field of lung cancer, including prevention, screening, nodule management, diagnosis, staging, and pre-operative evaluation. He has a particular interest in the discovery and validation of non-invasive molecular biomarkers.

Dr. Mazzone has led projects resulting in policy statements related to the "Components Necessary for High-Quality Lung Cancer Screening", "Quality Indicators for the Evaluation of Patients With Lung Cancer", and "Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer". He has participated in the development of policy statements related to smoking cessation in lung cancer screening, co-morbidities and lung cancer screening, implementation of lung cancer screening, and the identification of lung nodule research priorities. He led a recent update of guidelines for lung cancer screening for the American College of Chest Physicians and has participated in the development of lung nodule management guidelines. He has had leadership or advisory roles in organizations with an interest in lung cancer, including the ACCP, ATS, ALA, and ACS. He represented the ACCP and ATS in lung cancer screening advocacy efforts presented to CMS. He served as chair of the program committee for the ACCP's Chest 2017 meeting, and has been Chair of the Thoracic Oncology NetWork for Chest. He has previously served the Thoracic Oncology Assembly of the American Thoracic Society as a member of the Nominating Committee and Planning Committee, which he chaired from 2015-2017. He has recently been selected to be the next Editor-in-Chief of the journal CHEST.

## Anita McGlothlin

Anita McGlothlin joined the GO<sub>2</sub> Foundation for Lung Cancer in 2018 as the Director of Economics and Health Policy. Founded by patients and survivors, it is their mission to save, extend, and improve the lives of those vulnerable, at-risk, and diagnosed with lung cancer. Within this role, Anita advances lung cancer screening and care through health policy, regulatory, and coverage and reimbursement efforts.

Anita works closely with Patient and Outreach Services and Science and Research programs to advance the Foundation's mission through the development and implementation of health policies. With over twenty years of experience in economics and health policy, and having led low dose CT lung cancer screening national coverage efforts with radiology in her prior role, Anita has a special interest in reducing patient access barriers and increasing the lung cancer screening and survival rates.

With a focus on public policy, Anita continues her work in lung cancer patient advocacy by serving on the National Lung Cancer Roundtable (NLCRT) Policy Action Task Group, and formerly served as their Vice-Chair.

## Katherine Miller

Katy Miller is the US Franchise Head for Lung Cancer at AstraZeneca Oncology, overseeing the US commercial activities for Tagrisso. She has held various leadership roles within sales, marketing, insights, and finance, with a primary focus in lung cancer. Katy's professional experience has spanned across oncology, immunology, ophthalmology and other specialty disease areas, and across pipeline, pre-launch, launch, and mature indications, including roles at Human Genome Sciences and Genentech prior to joining AstraZeneca in 2012. Katy holds an MBA from Stanford University, a CFA charter, and a BA from the University of Pennsylvania.

# Speaker Biosketches

## Timothy Mullett, MD, MBA

Timothy Mullett, MD, is a Professor of Surgery in the Division of Cardiothoracic Surgery, Department of Surgery at the University of Kentucky. Since the project's inception in 2000, he has served on the Kentucky Lung Cancer Research Project (KLCRP) Governance Board, overseeing and directing the initiatives and funds of the KLCRP and serves as the Medical Director of the Kentucky Clinical Trials Network, an initiative of the KLCRP, which is a statewide network of sites conducting lung cancer trials. He serves as the Medical Director of the Markey Cancer Center Affiliate Network created to provide high-quality cancer care closer to home at collaborating centers, through specialty services, education and outreach programs. In addition, Dr. Mullett serves as the Medical Director of the Markey Cancer Center Research Network, a collaborative network of sites conducting a portfolio of high priority trials, including therapeutic oncology trials, interventional and non-interventional trials. He serves as Investigator and co-Investigator on numerous research grants funded by the Bristol Myers Squibb Foundation, and the Kentucky Lung Cancer Research Program. He also serves as co-Investigator of the Kentucky LEADS Collaborative, a portfolio of studies to reduce the burden of lung cancer in Kentucky through the development, evaluation and dissemination of novel, community-based interventions to promote clinician education, survivorship care and prevention and early detection of lung cancer. He serves as the co-chair of a LEADS Collaborative study, C3, to examine dissemination and implementation of lung cancer screening, an investigator-initiated trial of the Markey Cancer Center conducted throughout the state of Kentucky. His research interests also include a portfolio of studies on lung cancer screening, including shared decision making, serum biomarkers for lung cancer screening, development and delivery of continuing medical education series for lung cancer screening programs, primary care and other healthcare practitioners on lung cancer screening. Dr. Mullett has been active with the Commission on Cancer for several years and was recently nominated and is the current Chair for the CoC.

## Ronald Myers, DSW, PhD

Ronald E. Myers, DSW, PHD is currently Professor of the Division of Population Science and Director of the Center for Health Decisions in the Department of Medical Oncology of the Sidney Kimmel Cancer Center at Thomas Jefferson University. He has been actively involved in cancer prevention and control research for 40 years. During this time, he has served as the Principal Investigator of numerous peer-reviewed research grants funded by the National Cancer Institute, American Cancer Society, Centers for Disease Control and Prevention, Department of Defense, and the Patient Centered Outcomes Research Institute, and has published extensively in the field. His areas of expertise include patient adherence to cancer screening, physician follow-up of abnormal cancer screening test results, preference-based tailored navigation, shared decision making in cancer prevention and control, and disparities in cancer care. He has led numerous studies of patient decision making in genetic risk assessment, colorectal cancer screening, lung cancer screening, prostate cancer screening, lung cancer treatment, and prostate cancer treatment. In addition, he led an infrastructure project that aimed to developing a health systems-based learning community approach for use in the adaptation and implementation effective, evidence-based cancer screening intervention strategies in health systems. He is currently Co-PI on a Bristol Myers Squibb Foundation-funded implementation science project that aims to increase lung cancer screening in vulnerable populations, a co-I on an NIH-funded study on shared decision making in lung cancer screening among primary care patients, and a co-I on a study of shared decision making in colorectal cancer screening among Asian immigrants.

# Speaker Biosketches

## Jennifer Norton

Jen Norton leads Coverage & Pricing, Value Strategy & Marketing, and Contract Operations for the US Oncology and General Medicine commercial business units at Amgen. Prior to joining Amgen Jen was most recently Vice President, Market Access & Reimbursement at Biogen, where she oversaw all US pricing and access functions for their Multiple Sclerosis and Spinal Muscular Atrophy programs, as well as market preparation activities for Alzheimer's therapies. Prior to Biogen, Jen was Senior Director of Pricing and Contract Administration at Vertex Pharmaceuticals, and Senior Director of Life Sciences Strategy at iMany.

## Jessica Olson, PhD, MPH

Jessica Olson, PhD, MPH, is an Assistant Professor in the Institute for Health & Equity at the Medical College of Wisconsin. Her research is dedicated toward leveraging and integrating the strengths of basic, clinical, and community research to reduce disparities in breast and lung cancer incidence and mortality. Currently, she is a faculty member on the Advancing a Healthier Wisconsin Endowment's Cross-Cutting Initiative, an eight-year investment focused on reducing breast and lung cancer disparities in Wisconsin. Independently, she is collaborating on projects to identify circulating biomarkers that indicate cancer incidence, tumor progression, or subsequent cancer treatment-induced cardiotoxicity.

## Ray U. Osarogiagbon, MBBS, FACP

Dr. Osarogiagbon is Chief Scientist at the Baptist Memorial Healthcare Corporation, Director of the Multidisciplinary Thoracic Oncology Program and the Thoracic Oncology Research (ThOR) Group at the Baptist Cancer Center, in Memphis, Tennessee. He is the Principal Investigator of three ongoing National Institutes of Health-funded research projects: 2 R01 CA172253-01 (*'Improving pathologic nodal staging of resected lung cancer'*); 2UG1CA189873 (*'Baptist Health System/ Mid-South NCORP Minority Underserved Consortium'*) and 1UM1CA233080-01 (*'SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice'*). He is also Principal Investigator of IH-1304-6147, *'Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology,'* funded by the Patient-Centered Outcomes Research Institute.

Dr. Osarogiagbon is a Research Professor at Vanderbilt University, and a Research Member of the Vanderbilt Ingram Cancer Center. He is board certified in the Internal Medicine subspecialties of Hematology and Medical Oncology, a Fellow of the American College of Physicians and belongs to several professional societies including the Alpha Omega Alpha Honor Medical Society, American Society of Clinical Oncology, American Society of Hematology, the Fleischner Society, and the International Association for the Study of Lung Cancer.

Dr. Osarogiagbon's research interests center around improving population-level outcomes of cancer care by improving systems of care-delivery, improving the accuracy of cancer staging and evaluating the biologic drivers of outcome differences in potentially curable lung cancer. He is a member of the Cancer Prevention Steering Committee of the National Cancer Institute and a member of the Staging and Prognostic Factors Committee of the International Association for the Study of Lung Cancer.

# Speaker Biosketches

## Jamie Ostroff, PhD

Jamie Ostroff is the Joseph Gaumont Chair of Cancer Prevention, Chief, Behavioral Sciences Service and Vice Chair for Research and Co-Director of the Tobacco Treatment, Training and Research Lab in the Department of Psychiatry & Behavioral Sciences at Memorial Sloan Kettering Cancer Center (MSKCC). Dr. Ostroff's work focuses on developing, evaluating and implementing innovative, interventions to promote tobacco cessation, particularly among cancer patients, those seeking lung cancer screening, low income smokers, and other vulnerable populations. Dr. Ostroff has published 150+ peer-reviewed papers demonstrating expertise in the assessment and treatment of tobacco dependence, tobacco-related health disparities and lung cancer stigma. As part of the NCI-funded, SCALE Collaboration, Dr. Ostroff is currently co-leading a multi-site clinical trial testing various approaches for treating tobacco dependence in the context of lung cancer screening. Dr. Ostroff has clinical expertise addressing the challenges associated with delivery of tobacco treatment in routine cancer care and serves as Director of MSKCC's Tobacco Treatment Program, providing behavioral counseling and pharmacotherapy for tobacco dependent cancer patients. Dr. Ostroff has served on the NCI/AACR Task Force on Assessment of Tobacco Use, the ASCO Tobacco Control Subcommittee of Cancer Prevention Committee, and currently serves on the Expert Panel of the Cancer Centers Cessation Initiative (C3I) and the Scientific Leadership Board of the Go2Foundation for Lung Cancer. She serves on the Steering Committee and Co-Chairs the Tobacco Treatment Task Group of the National Lung Cancer Roundtable of the American Cancer Society.

## Gregory Riely, MD, PhD

Dr. Gregory Riely is a medical oncologist in the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center and the Weill Cornell Medical College. He is Vice Chair, Clinical Research in the Department of Medicine at Memorial Sloan Kettering. His primary research focus is in clinical research for patients with non-small cell lung cancer. Dr. Riely received his BA from The Johns Hopkins University, and his PhD and MD degrees from Case Western Reserve University. He completed fellowship training in Medical Oncology at Memorial Sloan-Kettering Cancer. He has authored and co-authored numerous peer-reviewed articles.

## M. Patricia Rivera, MD, FATS, FCCP

Dr. Rivera is a Professor of Medicine in the Pulmonary and Critical Care Medicine Division, Department of Medicine at the University of North Carolina at Chapel Hill in Chapel Hill, North Carolina. Dr. Rivera joined the University of North Carolina at Chapel Hill faculty in 1995. She is Co-Director of the Multidisciplinary Thoracic Oncology Program, a Program that she cofounded in 1995, Director of the Lung Cancer Screening Program, and Director of the Pulmonary Function and Bronchoscopy Laboratories. Dr. Rivera received her M.D. from the State University of New York at Stony Brook in New York. She did her Internship and Residency in Internal Medicine at North Shore University Hospital in Manhasset, New York. She completed a Pulmonary Medicine/Critical Care Fellowship at Memorial Sloan-Kettering Cancer Center in New York, New York. Dr. Rivera has held numerous leadership positions including Chair of American Thoracic Society (ATS) Thoracic Oncology Assembly and Chair of the Thoracic Oncology Network of CHEST. In 2020 she was elected as Secretary-Treasurer of ATS and will serve as president of the organization in 2023 and selected as a member of the ABIM Pulmonary Exam Committee.



# Speaker Biosketches

Dr. Rivera co-developed and serves as Co-Investigator of the North Carolina (NC) Lung Screening Registry. She collaborates with colleagues at UNC on several NIH/NCI funded grants to examine the delivery, quality and outcomes of lung cancer screening, the extent to which disparities in lung cancer screening outcomes exist, and the extent to which patient comorbidities and functional status impact lung cancer screening outcomes. She recently collaborated on a multi-institution pilot project exploring presence of coronary artery calcification on lung cancer screening CT and downstream risk stratification and statin delivery and exploring rural/urban disparities associated with biomarker testing in advanced lung cancer.

Dr. Rivera has received several honors and awards, including elected Secretary-Treasurer of the American Thoracic Society, the 2019 Assembly on Thoracic Oncology Lifetime Achievement Award, the 2019 Latin Medical Student Association Inaugural CHARLA Lecture 2019, the 2017 CHEST Presidential Honor Lecture, the 1998 University of North Carolina School of Medicine Whitehead Lecturer, the 2005 University of North Carolina White Coat Ceremony Keynote Speaker, and was nominated for the Humanitarian in Medicine award in 2004.

## Liora Sahar, PhD, GISP

Liora Sahar, PhD, is a Scientific Director for Geospatial Research within the Statistics & Evaluation Research Center at the American Cancer Society. The focus of her work is to engage the GIS team in geospatial research with applications to ACS mission. She is a geodetic engineer, GIS Professional and serves as adjunct faculty at GA-Tech. She also led and supported projects and research within Northrop Grumman corporation and multiple centers within the CDC.

## Kim Lori Sandler, MD

Dr. Sandler is a Nashville native who completed her undergraduate education at Emory University and both medical school and residency at Vanderbilt University. She trained as a cardiothoracic radiologist and joined the Vanderbilt faculty as an Assistant Professor in 2015.

Dr. Sander is a clinician-scientist and has served as the Co-Director of the Vanderbilt Lung Screening Program since 2016. She is passionate about screening for lung cancer and has designed initiatives to promote enrollment of patients in the lung screening program. She is a women's health advocate who is working to leverage the success of screening for breast cancer to improve enrollment of women in lung screening. In addition to women's health,

Dr. Sandler has focused her academic efforts on underserved populations in her catchment area and has contributed to the growing body of literature addressing disparities in lung cancer screening.

## Gerard A. Silvestri, MD, MS, FCCP

Gerard Silvestri, MD, MS is a lung cancer pulmonologist with a career dedicated to the evaluation, management and improvement of outcomes of patients with this most common of malignancies. He began the first multidisciplinary lung cancer clinic in South Carolina, and now evaluates between 5 and 7 new lung cancers per week. His research is patient oriented clinical research directed towards nearly every aspect of lung cancer care, including lung cancer screening, disparities



# Speaker Biosketches

in cancer care, shared decision-making and the evaluation and management of pulmonary nodules all of which are germane to screening for lung cancer. He has a graduate degree in the evaluative clinical sciences, and apply these health services research techniques to many aspects of lung cancer. He has developed a national and international reputation in lung cancer screening, having served on the DSMB of the national PLCO screening trial representing the lung arm of the trial. MUSC was a site for the National Lung Screening Trial and Dr. Silvestri served on the epidemiology working group after completion of the study. He served as a section editor and author of the American College of Chest Physicians evidence based guidelines on the diagnosis and management of lung cancer and have coauthored the chapter on screening, and his lab is interested in the generalizability of the findings of the NLST as well as shared decision-making, disparities, risk stratification, and screen detected nodule evaluation and management. Dr. Silvestri participates as a Steering Committee member and Task Group Chair on the American Cancer Society's National Lung Cancer Screening Roundtable Steering Committee. To date, he has over 225 peer-reviewed journal publications, book chapters, and invited commentaries in clinical care and research of lung cancer.

## Robert A. Smith, PhD, FSBI

Dr. Smith is a cancer epidemiologist and Senior Vice President, Cancer Screening at the National Office of the American Cancer Society (ACS) in Atlanta, Georgia, and is an Adjunct Professor of Epidemiology at the Rollins School of Public Health, Emory University School of Medicine. His primary research interests are cancer epidemiology, evaluation of cancer prevention and early detection programs, quality assurance in the delivery of health services, and cancer rehabilitation and survivorship. He received his PhD from the State University of New York at Stony Brook in 1983. Prior to joining the staff at the ACS, he held positions with the Boston University School of Public Health and the Centers for Disease Control. At the ACS, he leads the development of cancer screening guidelines and special research and policy projects focused on cancer prevention and control. He is the author of over 300 peer-reviewed scientific articles, reports, and book chapters and serves on many international and national advisory committees and working groups. Dr. Smith is a founding member of the NCCRT and has served as its Co-Director for 20 years. He also is a founding member of the National Lung Cancer Roundtable and the Principal Investigator of the first 3-year supporting grant. Dr. Smith is an Honorary Fellow of the Society of Breast Imaging, received the Cancer Prevention Laurel for Outstanding National Leadership from the Prevent Cancer Foundation, and received the Medal of Honor from the International Agency for Research on Cancer.

## Anurag Singh, MD

Dr. Anurag K. Singh is a Radiation Oncologist and Professor at Roswell Park Comprehensive Cancer Center. He obtained his undergraduate degree from Yale University and MD from Washington University in Saint Louis where he also did his residency. His first position was at the National Cancer Institute. He has been at Roswell Park for the last 13 years and currently serves as Associate Dean of Graduate Medical Education for Career Development, Director of Radiation Research, and Leader of the Cell Stress and Biophysical Therapy Program. He has designed and executed clinical trials to investigate a variety of novel therapies. Over the last decade he has performed and published both pre-clinical and prospective clinical studies (single institution and international) on a variety of topics that have the potential to alter the therapeutic ratio including stereotactic body radiation therapy (SBRT.)





# Speaker Biosketches

## Brendon Stiles, MD

Brendon Stiles is an Associate Professor of Cardiothoracic Surgery at New York-Presbyterian Hospital, Weill Cornell Medicine. Dr. Stiles is a busy clinician, with expertise in the surgical management of lung cancer and other thoracic malignancies. He is also an active basic science researcher focused on lung cancer. Dr. Stiles is the Chair of the Board of Directors of the Lung Cancer Research Foundation. Dr. Stiles is also a member of numerous professional organizations, as well as a member of the National Lung Cancer Roundtable and the Association of Community Cancer Centers NSCLC Steering Committee. He is and active advocate for lung cancer research and for patients and a frequent moderator of #lcsm chats on Twitter.

## Jamie Studts, PhD, FSBM

Dr. Jamie L. Studts is a Professor of Medical Oncology at the University of Colorado School of Medicine and Scientific Director of Behavioral Oncology. Dr. Studts also serves as the Co-Leader for Cancer Prevention and Control program and Co-Director of the Population Health Shared Resource at the University of Colorado Cancer Center. Prior to joining the University of Colorado, Dr. Studts served as Professor of Behavioral Science at the University of Kentucky College of Medicine, Assistant Director for Cancer Prevention and Control, and Director of the Behavioral and Community-Based Research Shared Resource Facility at the University of Kentucky Markey Cancer Center. Dr. Studts is a licensed clinical health psychologist, and his interests address behavioral aspects of tobacco-related malignancies. His research develops and tests interventions to promote informed/shared decision making and behavior change among patients and clinicians regarding prevention, screening, and survivorship of lung and head/neck cancer. His research has been funded by NCI, NIDCR, NIDA, NIEHS, the Bristol-Myers Squibb Foundation, and the Kentucky Lung Cancer Research Program. Dr. Studts is the Principal Investigator of the Kentucky LEADS Collaborative, and he previously served on the Institute of Medicine National Cancer Policy Forum addressing Implementation of Lung Cancer Screening. He is a Fellow of the Society of Behavioral Medicine, a member of the Scientific Leadership Board for the GO<sub>2</sub> Foundation for Lung Cancer, and he recently joined the National Comprehensive Cancer Network's Lung Cancer Screening and Smoking Cessation Guideline Panels. Dr. Studts serves as a member of the Steering Committee for the American Cancer Society's National Lung Cancer Roundtable and Chairs the Survivorship, Stigma, and Nihilism Task Group. Recently, Dr. Studts joined the Steering Committee for the Lung Ambition Alliance. In 2019 he received the Centerstone Healthcare Advocacy award in recognition of his efforts to reduce the burden of lung cancer in Kentucky.

## Letitia Thompson, MPPA

With thirty years of experience in the field of public health and twenty years with the American Cancer Society, Letitia has done extensive work in the area of health care policy and disease prevention and control. Her early career was spent in policy development and implementation in the Medicare and Medicaid programs. She established the Ryan White AIDS Drug Program and Community-Based HIV Home Health Program for the state of Mississippi. As the Mississippi Immunization Director, her work led to the development of the Vaccine for Children Program and the state's first immunization registry. Her success in state mandates for vaccination resulted in her hire by Merck Pharmaceuticals Vaccine Division where she helped establish their public vaccine program. In the field of tobacco, Letitia served as Government Affairs and Community Grants Director for the Partnership for

# Speaker Biosketches

a Health Mississippi—the youth tobacco prevention program established by Attorney General Mike Moore, lead attorney on the Tobacco Industry Master Settlement lawsuit. During her career with the American Cancer Society, Letitia focused on establishing one of the organization's first division state systems program, establish HPV vaccination initiatives, expand regional patient transportation and increase colorectal cancer screening and health equity. She earned her Bachelor of Arts Degree in English from the University of Mississippi and her Master of Public Policy and Administration Degree from Jackson State University. She lives in Jackson, Mississippi with her husband Craig and daughter Angel.

## Carey C. Thomson, MD, MPH, FATS, FCCP

Dr. Carey Thomson is the Chief of Pulmonary and Critical Care Medicine and the Interim Chair of the Department of Medicine at Mount Auburn Hospital/Beth Israel Lahey Health in Cambridge, Massachusetts, and an Associate Professor at Harvard Medical School. Dr. Thomson is an expert in implementation medicine and education with a clinical concentration in lung cancer. She started and directs the Lung Cancer Screening and Thoracic Oncology Multidisciplinary Program at Mount Auburn and serves on the Beth Israel Lahey Health Thoracic Oncology Clinical Practice Group Steering Committee. She is involved in leading statewide and national efforts to improve implementation of programs to increase the detection of early stage lung cancer through both lung cancer screening and lung nodule pathways. She has a strong interest in technology and clinical navigation to impact these efforts. She serves as a Co-Chair of the Massachusetts Learning Collaborative on Lung Cancer Screening, the Planning Committee of the American Thoracic Society Thoracic Oncology Assembly, and on the Implementation and State Based Initiative Task Groups of the National Lung Cancer Roundtable. She has led a number of initiatives to improve clinical education and implementation of clinical practices' guidelines for practicing pulmonary and critical care physicians and currently serves on the ATS Quality Improvement and Implementation Committee. Dr. Thomson has also had a research career in epidemiology and public health concentrating on tobacco cessation and public health interventions for tobacco control. She mentors trainees in quality improvement around lung cancer screening and lung nodule surveillance both locally and nationally.

## Brenna VanFrank, MD, MSPH

Dr. Brenna VanFrank, MD, MSPH is the senior medical officer in the Office on Smoking and Health (OSH) at the Centers for Disease Control and Prevention (CDC). She is responsible for providing input on the medical aspects of OSH's scientific research and serves as a scientific and medical consultant for OSH programs and projects. Dr. VanFrank joined CDC in 2014 as an Epidemic Intelligence Service (EIS) officer and has worked in nutrition, obesity, emergency preparedness, tobacco, and the integration of healthcare and public health. Dr. VanFrank is board certified in pediatrics and preventive medicine and is a member of the national Delta Omega Honorary Society in public health.

# Speaker Biosketches

## Robert Volk, PhD

Dr. Robert Volk is a professor and deputy department chair in the Department of Health Services Research at The University of Texas MD Anderson Cancer Center. A decision scientist, he heads the Decision Support Lab and the Shared Decision Making Core of MD Anderson's NCI-funded Cancer Center Support Grant. His research focuses on shared decision making, a process wherein patients and their health care providers jointly make difficult clinical decisions when the optimal strategy is uncertain. His lab produces, tests, and disseminates decision support tools for decision making across the cancer care continuum. He was named the 2012 Outstanding Patient Educator, received a President's Recognition for Faculty Excellence award in 2016, a President's Recognition for Faculty Excellence in Education and Mentorship Advancement award in 2017, a President's Recognition of Faculty Excellence in Prevention Outreach Award in 2019, and was recipient the 2020 Robert M. Chamberlain Distinguished Mentor Award. His patient decision aids have received two Telly Awards and Platinum and two Gold Hermes Creative Awards for best film and video production in the area of health care. Dr. Volk is Co-Chair of the Steering Committee for the International Patient Decision Aid Standards (IPDAS) Collaboration, and co-leads an update of the evidence and standards used in development of patient decision aids. He was also a panel member for National Quality Forum's patient decision aid certification project, which led to publication of their new standards in 2017. His team has produced a number of decision aids, including the Lung Cancer Screening Tools for Patients and Clinicians for AHRQ, and the colorectal cancer screening shared decision making tools for the American Cancer Society. Currently, he serves as Chair of the Shared Decision Making Task Group of the National Lung Cancer Roundtable (NLCRT) supported by the American Cancer Society. His research in patient decision support has been funded by the National Cancer Institute, the Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and Prevention, the Patient-Centered Outcomes Research Institute (PCORI), and other non-federal sources.

## Graham Warren, MD, PhD

Dr. Warren is a radiation oncologist and Vice Chairman for Research in Radiation Oncology at the Medical University of South Carolina. His primary interest is in evaluating the biologic, clinical, behavioral, and financial aspects of tobacco use in cancer patients. He has been a contributing author for Surgeon General's Reports having contributing for sections demonstrating the adverse effects of smoking on cancer treatment outcomes. He has worked with institutional, regional, national, and international organizations and governments to address tobacco use through development of cessation programs, policy, guidelines, and treatment approaches to improve outcomes for cancer patients.

## Charles White, MD, FACR, FNASCI

Dr. Charles White is Professor of Radiology and Internal Medicine at the University of Maryland School of Medicine and the Director of Thoracic Imaging and Vice-Chairman for Clinical Affairs at the University of Maryland Medical Center. He received his training at Columbia-Presbyterian Medical Center in New York. Dr. White is certified by both the American Board of Radiology and the American Board of Internal Medicine. He has published widely in the areas of Cardiothoracic Radiology including lung cancer screening and co-directs the lung cancer screening program at University of Maryland. He is the Chairman of the Implementation Strategies Task Group of the NLCRT a member of the Fleischner Society, and past Editor-in-Chief of the Journal of Thoracic Imaging, Past-President of the Society of Thoracic Radiology and Past-President of the North American Society of Cardiac Imaging.

# Speaker Biosketches

## Douglas E. Wood, MD, FACS, FRCSEd

Dr. Douglas E. Wood is The Henry N. Harkins Professor and Chair of the Department of Surgery at University of Washington. Prior to that he was Professor and Endowed Chair in Lung Cancer Research in the Department of Surgery at the University of Washington, where he was the Chief of the Division of Cardiothoracic Surgery. Dr. Wood received his undergraduate and medical degrees from Harvard University and trained in General Surgery and Cardiothoracic Surgery at the Massachusetts General Hospital in Boston.

Dr. Wood is a world leader in thoracic surgery and thoracic oncology. He is past president of the Society of Thoracic Surgeons, Western Thoracic Surgical Association, Thoracic Surgery Foundation and Seattle Surgical Society, previously serving as Director of the American Board of Thoracic Surgery and Chair of the ACGME Thoracic RRC. Dr. Wood is currently the president of the Cardiothoracic Surgery Network (CTSNet). He serves as the chair of the National Comprehensive Cancer Network (NCCN) Lung Cancer Screening Panel, vice chair of the NCCN Non-Small Cell Lung Cancer Panel, and vice chair of the National Lung Cancer Roundtable of the American Cancer Society.

## Celeste Worth, MCHES

Celeste Worth has over 20 years of experience in cancer control and provider education. She is the Director of the LuCa National Training Network, a national center for primary care provider education on lung cancer care based at the University of Louisville. She was previously a co-investigator for the Provider Education component of the Kentucky LEADS Collaborative lung cancer project for four years. Ms. Worth is a Master Certified Health Education Specialist, as well as a Tobacco Treatment Specialist, and received her degree in Health Administration from the University of Kentucky. She has managed innovative statewide and national continuing medical education programs including "Providers Practice Prevention™," "Lung Cancer in Kentucky: Improving Patient Outcomes," and the award-winning "Lung Cancer and the Primary Care Provider," and presented their results at numerous national and international conferences. Ms. Worth has also co-authored a book chapter on tobacco use treatment in the soon to be published Lung Cancer: Standards of Care. She is a member of the National Lung Cancer Roundtable Provider Outreach Task Group, is chair of the CME Review Subgroup, and on the American College of Radiology Lung Cancer Screening 2.0 Steering Committee. She has developed and implemented nationally recognized breast and cervical cancer screening, tobacco treatment and lung cancer care education for over 15,000 multi-disciplinary healthcare providers and students.

# NLCRT Member Organizations

A Breath of Hope Lung Foundation  
AbbVie  
Academy of Oncology Nurse & Patient Navigators  
Advocate Aurora Lutheran General Hospital  
Aetna  
ALK Fusion  
ALK Positive  
American Academy of Family Physicians  
American Association for Thoracic Surgery  
American Association for Women in Radiology\*  
American Association of Nurse Practitioners  
American Association of Physicists in Medicine  
American Cancer Society  
American Cancer Society Cancer Action Network  
American College of Chest Physicians (CHEST)  
American College of Preventive Medicine  
American College of Radiology  
American College of Surgeons Commission on Cancer  
American Indian Cancer Foundation  
American Lung Association  
American Lung Cancer Screening Initiative\*  
American Medical Women's Association  
American Public Health Association  
American Society for Radiation Oncology  
American Society of Clinical Oncology  
American Society of Preventive Oncology  
American Telehealth Association  
American Thoracic Society  
Amgen  
Anne Arundel Medical Center\*  
Association for the Treatment of Tobacco Use and Dependence  
Association of Community Cancer Centers  
Association of State & Territorial Health Officials  
AstraZeneca  
Baptist Cancer Center\*  
Barbara Ann Karmanos Cancer Institute  
Beaumont Health System\*  
bioAffinity Technologies, Inc.  
Biodesix, Inc.  
Bristol-Myers Squibb  
Bristol-Myers Squibb Foundation  
CancerCare  
Cancer Support Community  
Caring Ambassadors  
Catch It In Time\*  
CDC Division of Cancer Prevention and Control  
CDC Office on Smoking and Health  
Center for Health Law & Policy Innovation of Harvard Law School  
Centers for Medicare and Medicaid Services  
Chris Draft Family Foundation  
Christiana Care Health System  
Citizens for Radioactive Radon Reduction  
Commoner Center, City University of New York  
Dana-Farber Cancer Institute  
Dusty Joy Foundation (LiveLung)  
EGFR Resisters\*  
Eli Lilly and Company  
Exact Sciences  
Fleischner Society  
Foundation Medicine  
Free ME From Lung Cancer  
Genentech  
Georgetown University Lombardi Cancer Center  
Georgia Lung Cancer Roundtable  
GO<sub>2</sub> Foundation for Lung Cancer  
GRAIL  
Guardant Health  
Health First Cancer Institute (Florida)  
Houston Methodist\*  
Humana  
Indian Health Service  
Intercultural Cancer Council  
International Association for the Study of Lung Cancer  
International Cancer Action Network  
International Early Lung Cancer Action Program  
Jefferson Health  
Kentucky LEADS Collaborative  
KRas Kickers  
Lehigh Valley Health Network  
Life and Breath  
LGBT HealthLink  
LuCa National Training Network  
LungCAN  
LUNgevity Foundation  
Lung Cancer Awareness Month (LCAM) Coalition

# NLCRT Member Organizations

Lung Cancer Initiative of North Carolina  
Lung Cancer Research Foundation  
Maimonides Medical Center  
Maine Lung Cancer Coalition  
Maryland Department of Health  
Medical Imaging & Technology Alliance  
MedMyne  
Medtronic  
Memorial Sloan Kettering Cancer Center  
MeVis Medical Solutions  
Moffitt Cancer Center  
Mount Sinai Health System\*  
National Alliance for Hispanic Health  
National Association of Chronic Disease Directors  
National Cancer Institute  
National Comprehensive Cancer Network  
National Minority Quality Forum  
North American Association of Central Cancer Registries  
North American Quitline Consortium  
Novartis  
Nucleix  
NYU Langone Health Perlmutter Cancer Center\*  
Oncimmune USA  
Optellum Ltd  
Patient Advocate Foundation  
Patient Centered Primary Care Coalition  
Pfizer, Inc.  
Prevent Cancer Foundation  
ProLung  
Quality Insights  
Riverain Technologies, LLC  
Kentucky Cancer Consortium

Ride Hard Breathe Easy  
ROS1ders\*  
Sanofi\*  
Seattle Cancer Care Alliance  
Siteman Cancer Center  
Society for Behavioral Medicine  
Society for Research on Nicotine and Tobacco  
Society for Public Health Education\*  
Society of Interventional Radiology  
Society of General Internal Medicine  
Society of Thoracic Radiology  
Society of Thoracic Surgeons  
Stanford Medicine  
Sustainable Healthy Communities, LLC  
Thermo Fischer Scientific  
UCSF Smoking Cessation Leadership Center  
UCSF Helen Diller Family Comprehensive Cancer Center\*  
University of Kansas Cancer Center  
University of Maryland School of Medicine  
University of Michigan Comprehensive Cancer Center  
University of Mississippi Cancer Center and Research Institute  
University of Virginia Cancer Center  
University of Wisconsin Carbone Comprehensive Cancer Center  
Upstage Lung Cancer  
Vanderbilt-Ingram Cancer Center  
VA-PALS (Partnership to Increase Access to Lung Screening)  
Veterans Health Administration  
VisionGate  
Wake Forest Comprehensive Cancer Center  
Yale Cancer Center

\*New NLCRT Members - 2020

# THANK YOU TO OUR NLCRT SPONSORS!

AstraZeneca 

AMGEN<sup>®</sup>  Bristol-Myers Squibb

Genentech  
*A Member of the Roche Group*

 NOVARTIS

*Lilly* | ONCOLOGY

SANOFI GENZYME 

Additional acknowledgement to Guardant Health and Foundation Medicine